Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MSH2 deletion + MSH6 deletion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MSH2 deletion + MSH6 deletion	Rectal Cancer	MSH2 deletion + MSH6 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 2wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
MSH2 deletion + MSH6 deletion	Endometrial Cancer	MSH2 deletion + MSH6 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4